

RECEIVED  
CENTRAL FAX CENTER


NOV 27 2006

### Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

### Listing of Claims

Claim 1. (Previously presented) A compound of formula I:



I.

or a pharmaceutically acceptable salt thereof, wherein:

R<sup>1</sup> is hydrogen, CHN<sub>2</sub>, R, or -CH<sub>2</sub>Y;

R is an aliphatic group, an aryl group, an alkyl group, a heterocyclic group, or a heterocyclylalkyl group;

Y is an electronegative leaving group;

R<sup>2</sup> is CO<sub>2</sub>H, CH<sub>2</sub>CO<sub>2</sub>H, or esters, amides or isosteres of CO<sub>2</sub>H or CH<sub>2</sub>CO<sub>2</sub>H, thereof;

X<sub>2</sub>-X<sub>1</sub> is N(R<sup>3</sup>)-C(R<sup>3</sup>) or N=C;

each R<sup>3</sup> is independently selected from hydrogen or C<sub>1-6</sub> aliphatic,

Ring C is a fused aryl ring, provided that the fused aryl ring has an unsubstituted carbon atom at the position adjacent to the -C(O)-N(-)- group in ring B that is adjacent to the side chain comprising R<sup>1</sup>;

n is 0, 1 or 2; and

each methylene carbon in Ring A is optionally and independently substituted by =O, or by one or more halogen, C<sub>1-4</sub> alkyl, or C<sub>1-4</sub> alkoxy.

Claim 2. (Previously presented) The compound of claim 1 having one or more of the following groups:

(a) R<sup>1</sup> is -CH<sub>2</sub>Y wherein Y is a halogen, OR, SR, or -OC=O(R), wherein R is an aryl group or heterocyclic group;

(b) R<sup>2</sup> is CO<sub>2</sub>H or esters, amides or isosteres of CO<sub>2</sub>H thereof;


- (c)  $X_2-X_1$  is  $N=C$ ;
- (d) Ring C is a fused five-membered aromatic ring having zero to two heteroatoms; and
- (e)  $n$  is 0 or 1.

Claim 3. (Previously presented) The compound of claim 2 wherein:

- (a)  $R^1$  is  $-CH_2Y$  wherein  $Y$  is a halogen, OR, SR, or  $-OC=O(R)$ , wherein  $R$  is an aryl group or heterocyclic group;
- (b)  $R^2$  is  $CO_2H$  or esters, amides or isosteres of  $CO_2H$  thereof;
- (c)  $X_2-X_1$  is  $N=C$ ;
- (d) Ring C is a fused six-membered aromatic ring having zero to two heteroatoms; and
- (e)  $n$  is 0 or 1.

Claim 4. (Previously presented) The compound of claim 3 wherein  $R^1$  is  $-CH_2Y$  wherein  $Y$  is F;  $R^2$  is  $CO_2H$  or an ester or amide thereof;  $X_2-X_1$  is  $N=C$ ; Ring C is benzene ring; and  $n$  is 0 or 1.

Claim 5. (Previously presented) The compound of claim 1, said compound selected from the compounds:



Example	$R^1$	$R^2$	Ring C	$n$	$X_1$	$X_2$
1	$CH_2F$	$CO_2H$	Benzo	0	C	N
2	$CH_2F$	$CO_2H$	Benzo	1	C	N
3	$CH_2F$	$CO_2H$	Benzo	0	C	C-H
4	$CH_2F$	$CO_2H$	Benzo	1	C	C-H
5	$CH_2F$	$CO_2H$	Benzo	1	N	C=O
6	$CH_2F$	$CO_2H$	Pyrazino	1	N	C=O

Claim 6. (Previously presented) A pharmaceutical composition comprising a compound as claimed in any of claims 1-5 and a pharmaceutically acceptable carrier.

Claims 7-8. (Canceled)

Claim 9. (Currently amended) A method for treating a disease or condition selected from osteoarthritis, ~~pancreatitis, adult respiratory distress syndrome, rheumatoid arthritis, cell preservation, or organ preservation,~~ chronic active hepatitis, psoriasis, graft vs host disease, sepsis, septic shock, cerebral ischemia, myocardial ischemia, myocardial infarction, congestive heart failure, atherosclerosis, coronary artery bypass graft, spinal muscular atrophy, neurological damage due to stroke, ulcerative colitis, traumatic brain injury, spinal cord injury, hepatitis B, and hepatitis C, comprising administering to a mammal in need of such a treatment a therapeutically effective amount of a compound as claimed in any of claims 1-5.

Claim 10. (Canceled)

Claim 11. (Previously presented) A method of preserving cells, said method comprising the step of bathing the cells in a solution of a compound as claimed in any of claims 1-5.

Claim 12. (Previously presented) A method of preserving an organ for organ transplant or for preserving a blood product, comprising the step of bathing the organ or blood product in a solution of a compound as claimed in any of claims 1-5.

Claims 13-14. (Canceled)